<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Urol</journal-id><journal-id journal-id-type="iso-abbrev">World J Urol</journal-id><journal-title-group><journal-title>World Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">0724-4983</issn><issn pub-type="epub">1433-8726</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407947</article-id><article-id pub-id-type="pmc">PMC12102097</article-id>
<article-id pub-id-type="publisher-id">5692</article-id><article-id pub-id-type="doi">10.1007/s00345-025-05692-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Laser vs. bipolar prostate vaporization in bleeding-prone patients: a randomized trial and cutting-edge analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shorbagy</surname><given-names>Ahmed A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ismail</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kotb</surname><given-names>Youssef M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Desouki</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shabayek</surname><given-names>Mohamed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4331-3715</contrib-id><name><surname>Hanna</surname><given-names>Peter</given-names></name><address><email>dr.peter444@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cb9w016</institution-id><institution-id institution-id-type="GRID">grid.7269.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 1570</institution-id><institution>Department of Urology, </institution><institution>Ain Shams University, </institution></institution-wrap>Cairo, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048qnr849</institution-id><institution-id institution-id-type="GRID">grid.417764.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 4699 3028</institution-id><institution>Department of Urology, </institution><institution>Aswan University, </institution></institution-wrap>Aswan, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>43</volume><issue>1</issue><elocation-id>322</elocation-id><history><date date-type="received"><day>31</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To compare effectiveness and safety of transurethral diode laser vaporization of prostate (diode LVP) versus bipolar transurethral vaporization of prostate (B-TUVP) in symptomatic benign prostatic hyperplasia (BPH) patients receiving oral anticoagulants/anti-platelet drugs.</p></sec><sec><title>Patients and methods</title><p id="Par2">All symptomatic prostate patients receiving oral anticoagulants/anti-platelet drugs are prospectively enrolled in the study between January 2023 to May 2024 in our institution. Of total 98 patients were randomized to B-TUVP (48 patients) or diode LVP (50 patients). The primary outcome is to compare B-TUVP with diode LVP regarding operative bleeding and postoperative hemoglobin drop. Secondary outcomes assess time of urinary irrigation, time of urethral catheter removal, length of hospital stays, and 6-month postoperative functional outcomes; IPSS, postoperative flow rate, and postvoid residual urine.</p></sec><sec><title>Results</title><p id="Par3">Baseline characteristics were similar in both groups. Diode LVP group had a significantly higher postoperative hemoglobin with a lower drop compared to B-TUVP group (p&#x02009;=&#x02009;0.032, p&#x02009;=&#x02009;0.007; respectively). The diode LVP group had a significantly reduced urinary irrigation duration compared to the B-TUVP group (p&#x02009;=&#x02009;0.031). Also, diode LVP patients had early catheter removal compared to those in the B-TUVP group (p&#x02009;=&#x02009;0.014). Additionally, the diode group had a notably reduced hospital stay duration compared to the B-TUVP group (p&#x02009;=&#x02009;0.024). There were no significant differences between both groups regarding 6-month postoperative IPSS, Q max and PVRU.</p></sec><sec><title>Conclusion</title><p id="Par4">Diode LVP of the prostate is a safer alternative for treating BPH with fewer risks compared to B-TUVP especially in patients receiving anticoagulants. Nonetheless, both treatments yield similar 6-months functional outcomes.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00345-025-05692-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bipolar electro vaporization</kwd><kwd>Diode laser</kwd><kwd>Bleeding tendency</kwd><kwd>Anticoagulant</kwd></kwd-group><funding-group><award-group><funding-source><institution>Ain Shams University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Benign prostatic hyperplasia (BPH) prevalence increases with age, affecting a significant portion of older males requiring treatment [<xref ref-type="bibr" rid="CR1">1</xref>]. Transurethral resection of the prostate (TURP) remains the standard surgical approach; however, concerns exist regarding perioperative bleeding [<xref ref-type="bibr" rid="CR2">2</xref>], particularly in patients with risk factors like diabetes, anticoagulation, and constipation [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">The potential for complications such as prolonged catheterization, rehospitalization for bleeding, and electrolyte imbalances has increased interest in modern surgical technologies. Consequently, bipolar and laser energy modalities are being increasingly adopted for prostate tissue resection, vaporization, ablation, or enucleation [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par7">In recent years, laser technologies have taken over the field of prostate resection, particularly for high-risk patients prone to bleeding or those on anticoagulants. The primary laser methods in use today include LBO (lithium borate), Diode lasers, Holmium yttrium&#x02013;aluminum-garnet laser (Ho-YAG), Thulium fiber laser (TFL), and Thulium YAG (Tm-YAG) [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par8">They offer remarkable hemostatic capabilities owing to their significant absorption by hemoglobin, yet their low water absorption results in slow ablative features, leading to extended operation duration [<xref ref-type="bibr" rid="CR8">8</xref>]. The semiconductor diode laser is considered superior for its hemostatic characteristics; however, its acceptance was diminished due to postoperative dysuria, discomfort, and urinary storage symptoms [<xref ref-type="bibr" rid="CR9">9</xref>]. A newly launched diode laser, functioning at a wavelength of 980 nm, showcases distinct characteristics through its innovative fiber design, enhanced tissue ablative properties, and effective hemostasis resulting from its notable concurrent absorption in water and hemoglobin [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par9">The Biolitec LEONARDO"dual 200 device emits wavelengths of 980 nm and 1470 nm. It is designed to combine excellent coagulation with tissue ablation, making it suitable for treating benign prostatic hyperplasia with transurethral vaporization of the prostate [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par10">Therefore, we aimed, in our study, to compare two different modalities in a prospective randomized fashion: Transurethral prostate vaporization with diode laser (diode LVP) versus bipolar transurethral vaporization of prostate (B-TUVP) in patients taking anticoagulant/anti-platelet medications.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Study population</title><p id="Par11">This prospective, randomized controlled trial, conducted at Ain Shams University Hospitals (Egypt) from January 2023 to May 2024, evaluated the short-term efficacy and safety of diode LVP versus B-TUVP in patients on anti-coagulant/anti-platelet medications with BPH (prostate size &#x0003c;&#x02009;60 gm) requiring prostatectomy, over a 6-month postoperative follow-up. Inclusion and exclusion criteria are listed in the supplementary Table 1. All prostatic patients who met the inclusion criteria in the timeline from January 2023 to May 2024 were enrolled in this study.</p><p id="Par12">Additionally, all our patients underwent standard laboratory tests and PSA screening, as well as pelvic ultrasound, to evaluate prostate size or perform a prostatic biopsy if necessary. Patients on antiplatelets (100 mg aspirin) continued therapy perioperatively without bridging. Oral anticoagulants (warfarin) were stopped 5&#x000a0;days pre-surgery and bridged with LMWH (40 mg/day) starting 2&#x000a0;days after, paused 12 h pre- and post-surgery, then overlapped with resumed warfarin until target INR. The study underwent rigorous ethical review and oversight, commencing with initial approval from the local Institutional Review Board (FWA 000017585). Continuous monitoring of each study phase was conducted by the committee, culminating in final approval upon verification of strict adherence to the approved protocol.</p></sec><sec id="Sec4"><title>Randomization</title><p id="Par13">Participants were equitably distributed between the diode laser vaporization of the prostate (diode LVP) and bipolar transurethral vaporization of the prostate (B-TUVP) treatment arms via a 1:1 randomization protocol, facilitated by an online randomization tool (<ext-link ext-link-type="uri" xlink:href="http://www.randomizer.at">www.randomizer.at</ext-link>).</p></sec><sec id="Sec5"><title>Operative procedure</title><p id="Par14">Operative procedures of bipolar electrovaporization were described previously [<xref ref-type="bibr" rid="CR11">11</xref>]. The other group of patients were subjected to the 980-nm 200-W high-power diode laser vaporization. We used a 200-W machine (LEONARDO Dual 200, Biolitec, Germany) to generate a 980-nm laser through a diode semiconductor.</p></sec><sec id="Sec6"><title>Outcomes</title><p id="Par15">The primary outcome is to compare two techniques (B-TUVP vs. diode LVP) in the treatment of BPH regarding post-operative bleeding in term of postoperative hemoglobin drop.</p><p id="Par16">Secondary outcomes assess the time of urinary irrigation (hours), time of urethral catheter removal (days), length of hospital stays (days), and 6-month postoperative functional outcomes (IPSS, postoperative flow rate, and PVRU).</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par17">All comparisons were performed between categorical variables using the Chi-square test and Fisher&#x02019;s exact test and between continuous variables using the student&#x02019;s <italic>t</italic> test if parametric and Mann&#x02013;Whitney test if non-parametric. The comparison between two paired groups regarding quantitative data and parametric distribution was done by using a <italic>Paired t test</italic><bold><italic>.</italic></bold> SPSS v.25 (IBM Corp, Armonk, NY, USA) was used to perform all statistical analyses. <italic>P</italic> values &#x0003c;&#x02009;0.05 were taken to indicate statistical significance.</p><p id="Par18">Sample size estimation was carried out utilizing PS Power and Sample Size Calculations Software (version 3.0.11 for MS Windows, William D. Dupont and Walton D. Vanderbilt, Department of Biostatistics, Vanderbilt University, Nashville, TN, USA). Prior to the initiation of this research, a randomized controlled trial (RCT) directly comparing (diode LVP) and (B-TUVP) in patients undergoing anticoagulant therapy was absent from the published literature. A clinically significant difference of 1-g in hemoglobin loss, designated as the primary outcome measure, was hypothesized [<xref ref-type="bibr" rid="CR12">12</xref>]. A sample size of 40 participants per treatment arm was determined via Student's t test, employing a power of 90%, an alpha level of 0.05, and a 1:1 allocation ratio. To mitigate potential attrition and ensure adequate statistical power, the sample size was augmented by 20%, resulting in a final target of about 48 participants per group.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par19">A prospective randomized study involved 98 patients with BPH. A total of 48 patients in the B-TUVP group and 50 patients in the diode LVP group were analyzed and compared. The CONSORT flow chart is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart for study participants</p></caption><graphic xlink:href="345_2025_5692_Fig1_HTML" id="MO1"/></fig></p><p id="Par20">The baseline characteristics of both groups are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There were no significant changes between both groups regarding age, preoperative IPSS, Q-Max, and PVRU.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison between bipolar and diode groups regarding demographic data and baseline characteristics of the patients studied</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2"/><th align="left">Bipolar</th><th align="left" colspan="2">Diode</th><th align="left" rowspan="2">P value</th></tr><tr><th align="left">No. =&#x02009;48</th><th align="left" colspan="2">No. =&#x02009;50</th></tr></thead><tbody><tr><td align="left" rowspan="2">Age</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">60.96 &#x000b1;&#x02009;6.76</td><td align="left">60.77 &#x000b1;&#x02009;6.24</td><td char="." align="char" rowspan="2" colspan="2">0.916<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">50&#x02013;72</td><td align="left">50&#x02013;69</td></tr><tr><td align="left" rowspan="2">Prostate size (ml)</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">54.4 &#x000b1;&#x02009;4.2</td><td align="left">51.7 &#x000b1;&#x02009;7.9</td><td char="." align="char" rowspan="2" colspan="2">0.323<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">45&#x02013;60</td><td align="left">42&#x02013;58</td></tr><tr><td align="left" rowspan="2">Preoperative hemoglobin</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">12.46 &#x000b1;&#x02009;1.89</td><td align="left">12.34 &#x000b1;&#x02009;3.75</td><td char="." align="char" rowspan="2" colspan="2">0.968<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">9.3&#x02013;15.6</td><td align="left">9.5&#x02013;15</td></tr><tr><td align="left">Charleson Comorbidity index</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char" rowspan="4" colspan="2">0.201<sup>b</sup></td></tr><tr><td align="left">&#x000a0;Mild (G1, 2)</td><td align="left">No. (%)</td><td align="left">14 (29.2%)</td><td align="left">17 (34%)</td></tr><tr><td align="left">&#x000a0;Moderate (G3, 4)</td><td align="left">No. (%)</td><td align="left">18 (37.5%)</td><td align="left">20 (40%)</td></tr><tr><td align="left">&#x000a0;Severe (&#x02265; 5)</td><td align="left">No. (%)</td><td align="left">16 (33.3%)</td><td align="left">13 (26%)</td></tr><tr><td align="left">Anticoagulant/Antiplatelet</td><td align="left"/><td align="left"/><td align="left"/><td char="." align="char" rowspan="3" colspan="2">0.921<sup>b</sup></td></tr><tr><td align="left">&#x000a0;LMWH</td><td align="left">No. (%)</td><td align="left">23 (47.9%)</td><td align="left">24 (48%)</td></tr><tr><td align="left">&#x000a0;Aspirin</td><td align="left">No. (%)</td><td align="left">25 (53.1%)</td><td align="left">26 (52%)</td></tr><tr><td align="left" rowspan="2">IPSS</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">23.76 &#x000b1;&#x02009;3.71</td><td align="left">23.69 &#x000b1;&#x02009;3.42</td><td char="." align="char" rowspan="2" colspan="2">0.932<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">17&#x02013;32</td><td align="left">16&#x02013;29</td></tr><tr><td align="left" rowspan="2">Q max</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">10.32 &#x000b1;&#x02009;1.42</td><td align="left">9.75 &#x000b1;&#x02009;1.51</td><td char="." align="char" rowspan="2" colspan="2">0.727<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">6.90&#x02013;13.10</td><td align="left">7.2&#x02013;13.0</td></tr><tr><td align="left" rowspan="2">PVRU</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">126.24 &#x000b1;&#x02009;45.77</td><td align="left">118.44 &#x000b1;&#x02009;58.45</td><td char="." align="char" rowspan="2" colspan="2">0.634<sup>a</sup></td></tr><tr><td align="left">Range</td><td align="left">33&#x02013;200</td><td align="left">30&#x02013;300</td></tr></tbody></table><table-wrap-foot><p>P value &#x0003e;&#x02009;0.05: Non-significant (NS); P value &#x0003c;&#x02009;0.05: Significant (S); P value &#x0003c;&#x02009;0.01: Highly significant (HS)</p><p><sup>*</sup>Superscript letter (a) refers to comparisons using independent T test</p><p><sup>*</sup>Superscript letter (b) refers to comparisons using Chi square test</p></table-wrap-foot></table-wrap></p><sec id="Sec9"><title>Postoperative outcomes</title><p id="Par21">There was no significant difference between studied groups regarding preoperative hemoglobin level (P =&#x02009;0.968), but post-hemoglobin was significantly higher in the diode group than B-TUVP group (P =&#x02009;0.032) with hemoglobin drop being less in the diode group than in the B-TUVP group (P =&#x02009;0.007). The diode LVP group showed a significantly shorter urinary irrigation time (mean &#x000b1;&#x02009;SD 13.44 &#x000b1;&#x02009;11.32 h) compared to the B-TUVP group (mean &#x000b1;&#x02009;SD 24.15 &#x000b1;&#x02009;16.43 h) (p =&#x02009;0.031). Similarly, diode LVP patients showed early catheter removal (mean &#x000b1;&#x02009;SD 1.34 &#x000b1;&#x02009;0.83 days) compared to the B-TUVP group (mean &#x000b1;&#x02009;SD 2.46 &#x000b1;&#x02009;1.12 days) (p =&#x02009;0.014). Also, the diode LVP group showed a significantly shortened length of hospital duration compared to the B-TUVP group (mean &#x000b1;&#x02009;SD 2.31 &#x000b1;&#x02009;0.99 days vs. 3.65 &#x000b1;&#x02009;1.12 days; respectively) (p =&#x02009;0.024) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Postoperative outcomes in bipolar and diode patient groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2">Postoperative outcomes</th><th align="left">Bipolar</th><th align="left">Diode</th><th align="left" colspan="2">95% (CI) of mean difference</th><th align="left" rowspan="2">P value</th></tr><tr><th align="left">No. =&#x02009;48</th><th align="left">No. =&#x02009;50</th><th align="left">Lower</th><th align="left">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="2">Postoperative hemoglobin</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">10.34 &#x000b1;&#x02009;1.29</td><td align="left">11.18 &#x000b1;&#x02009;1.47</td><td char="." align="char">&#x02013; 1.33</td><td char="." align="char">0.29</td><td char="." align="char" rowspan="2">0.032</td></tr><tr><td align="left">Range</td><td align="left">9.20&#x02013;14.40</td><td align="left">9.50&#x02013;14.20</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left">Hemoglobin drop</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">1.83 &#x000b1;&#x02009;1.23</td><td align="left">0.81 &#x000b1;&#x02009;0.82</td><td char="." align="char">&#x02013; 1.21</td><td char="." align="char">0.14</td><td char="." align="char">0.007</td></tr><tr><td align="left" rowspan="2">Urinary irrigation (hours)</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">24.15 &#x000b1;&#x02009;16.43</td><td align="left">13.44 &#x000b1;&#x02009;11.32</td><td char="." align="char">&#x02013; 3.86</td><td char="." align="char">11.25</td><td char="." align="char" rowspan="2">0.031</td></tr><tr><td align="left">Range</td><td align="left">12&#x02013;48</td><td align="left">12&#x02013;48</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2"><p>Urethral catheter</p><p>removal/day</p></td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">2.46 &#x000b1;&#x02009;1.12</td><td align="left">1.34 &#x000b1;&#x02009;0.83</td><td char="." align="char">&#x02013; 0.15</td><td char="." align="char">1.07</td><td char="." align="char" rowspan="2">0.014</td></tr><tr><td align="left">Range</td><td align="left">1&#x02013;4</td><td align="left">1&#x02013;4</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">Length of hospital stays (days)</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">3.65 &#x000b1;&#x02009;1.12</td><td align="left">2.31 &#x000b1;&#x02009;0.99</td><td char="." align="char">&#x02013; 0.15</td><td char="." align="char">1.08</td><td char="." align="char" rowspan="2">0.024</td></tr><tr><td align="left">Range</td><td align="left">2&#x02013;5</td><td align="left">2&#x02013;5</td><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">IPSS</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">8.23 &#x000b1;&#x02009;2.43</td><td align="left">8.21 &#x000b1;&#x02009;3.29</td><td char="." align="char">&#x02013; 1.72</td><td char="." align="char">1.49</td><td char="." align="char">0.886</td></tr><tr><td align="left">Range</td><td align="left">5&#x02013;14</td><td align="left">1&#x02013;16</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">Q max</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">17.23 &#x000b1;&#x02009;1.75</td><td align="left">18.45 &#x000b1;&#x02009;3.27</td><td char="." align="char">&#x02013; 1.49</td><td char="." align="char">1.44</td><td char="." align="char">0.975</td></tr><tr><td align="left">Range</td><td align="left">13&#x02013;20</td><td align="left">11&#x02013;23</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">PVRU</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">126.24 &#x000b1;&#x02009;45.77</td><td align="left">37.39 &#x000b1;&#x02009;15.38</td><td char="." align="char">&#x02013; 8.61</td><td char="." align="char">8.30</td><td char="." align="char">0.971</td></tr><tr><td align="left">Range</td><td align="left">20&#x02013;60</td><td align="left">0&#x02013;70</td><td char="." align="char"/><td char="." align="char"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>P value &#x0003e;&#x02009;0.05: Non-significant (NS); P value &#x0003c;&#x02009;0.05: Significant (S); P value &#x0003c;&#x02009;0.01: Highly significant (HS)</p><p><sup>*</sup>All comparisons using independent T test</p></table-wrap-foot></table-wrap></p><p id="Par22">There were no significant differences between both groups regarding postoperative complications (supplementary Table 2).</p><p id="Par23">Regarding functional outcomes, The IPSS and PVRU were significantly lower in 6&#x000a0;months postoperative compared to preoperative in B-TUVP and diode cases (p &#x0003c;&#x02009;0.001, p&#x02009;&#x0003c; 0.001 respectively). Q max was significantly higher in 6&#x000a0;months postoperative compared to the baseline preoperative values in B-TUVP and diode case (p &#x0003c;&#x02009;0.001; p&#x02009;&#x0003c; 0.001; respectively) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>preoperative and 6&#x000a0;months postoperative values of IPSS, Q-max and PVRU in bipolar patients vs. diode patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" rowspan="2"/><th align="left" colspan="2">Bipolar (No. 48)</th><th align="left">Differences</th><th align="left" rowspan="2">P value</th><th align="left">Diode (No. 50)</th><th align="left"/><th align="left">Differences</th><th align="left" rowspan="2">P value</th></tr><tr><th align="left">Preoperative</th><th align="left">6 months postoperative</th><th align="left">Mean &#x000b1;&#x02009;SD</th><th align="left">Preoperative</th><th align="left">6 months postoperative</th><th align="left">Mean &#x000b1;&#x02009;SD</th></tr></thead><tbody><tr><td align="left" rowspan="2">IPSS</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">23.76 &#x000b1;&#x02009;3.71</td><td align="left">8.23 &#x000b1;&#x02009;2.43</td><td align="left">&#x02013; 15.53 &#x000b1;&#x02009;3.42</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td><td align="left">21.34 &#x000b1;&#x02009;3.75</td><td align="left">8.21 &#x000b1;&#x02009;3.29</td><td align="left">&#x02013; 13.13 &#x000b1;&#x02009;3.98</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Range</td><td align="left">17&#x02013;32</td><td align="left">5&#x02013;14</td><td align="left"/><td char="." align="char"/><td align="left">16&#x02013;29</td><td align="left">1&#x02013;16</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">Q max</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">10.32 &#x000b1;&#x02009;1.42</td><td align="left">17.23 &#x000b1;&#x02009;1.75</td><td align="left">6.91 &#x000b1;&#x02009;1.55</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td><td align="left">9.75 &#x000b1;&#x02009;1.51</td><td align="left">18.45 &#x000b1;&#x02009;3.27</td><td align="left">8.70 &#x000b1;&#x02009;3.12</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Range</td><td align="left">6.90&#x02013;13.10</td><td align="left">13&#x02013;20</td><td align="left"/><td char="." align="char"/><td align="left">7.2&#x02013;13</td><td align="left">11&#x02013;23</td><td align="left"/><td char="." align="char"/></tr><tr><td align="left" rowspan="2">PVRU</td><td align="left">Mean &#x000b1;&#x02009;SD</td><td align="left">126.24 &#x000b1;&#x02009;45.77</td><td align="left">33.47 &#x000b1;&#x02009;11.53</td><td align="left">&#x02013; 92.77 &#x000b1;&#x02009;46.24</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td><td align="left">118.44 &#x000b1;&#x02009;58.45</td><td align="left">37.39 &#x000b1;&#x02009;15.38</td><td align="left">&#x02013; 81.05 &#x000b1;&#x02009;53.89</td><td char="." align="char">&#x02009;&#x0003c; 0.001</td></tr><tr><td align="left">Range</td><td align="left">33&#x02013;200</td><td align="left">20&#x02013;60</td><td align="left"/><td char="." align="char"/><td align="left">30&#x02013;300</td><td align="left">0&#x02013;70</td><td align="left"/><td char="." align="char"/></tr></tbody></table><table-wrap-foot><p>P value &#x0003e;&#x02009;0.05: Non-significant (NS); P value &#x0003c;&#x02009;0.05: Significant (S); P value &#x0003c;&#x02009;0.01: Highly significant (HS)</p><p><sup>*</sup>All comparisons using independent T test</p></table-wrap-foot></table-wrap></p><p id="Par24">There were no significant differences between both groups regarding 6-month postoperative IPSS, Q max, and PVRU (p =&#x02009;0.874, p&#x02009;= 0.921, p&#x02009;= 0.971; respectively) (supplementary Table 3).</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par25">Navigating the therapeutic landscape for symptomatic benign prostatic hyperplasia (BPH) presents a complex decision-making process for clinicians. The modalities now encompass medical therapy, minimally invasive procedures, TURP, laser surgery, and open surgery for the prostate. Key factors to consider in making treatment decisions are efficacy, long-lasting results, frequency of complications, length of hospital stay and catheter use, and cost analysis [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par26">Technological advancements enable precise and effective prostate enucleation via various laser modalities offering resection, vaporization, or enucleation. Laser enucleation facilitates the complete resection of prostatic adenomas, irrespective of their dimensions with simultaneous hemostasis. However, widespread laser adoption, especially in developing countries, faces hurdles including cost, a significant learning curve, limited equipment, and insufficient expertise [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par27">Authorized in 2007, the 980 nm diode laser has become popular for BPH treatment due to its potent vaporization and coagulation. Its simultaneous absorption by water and hemoglobin ensures efficient tissue ablation and effective hemostasis [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par28">To our knowledge, it&#x02019;s the first study comparing the efficacy of transurethral bipolar vaporization of prostate (B-TUVP) versus diode LVP for symptomatic BPH patients taking anti-coagulant/anti-platelet medications.</p><p id="Par29">We prospectively compared two techniques in the treatment of BPH (diode-LVP using the Biolitec Leonardo dual 200 device diode laser and B-TUVP) concerning postoperative bleeding, safety, and efficacy (hospital stay, time of urethral catheter removal, flow rate, post-voiding residual urine, and IPSS) in patients with bleeding tendencies.</p><p id="Par30">The diode LVP group of patients showed less bleeding, and less hemoglobin drop compared to the B-TUVP group. In the same context, Kai-Yi Tzou et al. showed significantly less hemoglobin drop in patients managed by diode laser with bipolar TURP compared to conventional monopolar TURP [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par31">On the other hand, a randomized clinical trial conducted by Mohammad et al. showed no differences regarding postoperative hemoglobin level between the diode laser group and the TURP group [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par32">That difference is attributed to that diode lasers exhibit simultaneous absorption in both water and hemoglobin, making them suitable for effective tissue ablation while ensuring superior hemostasis. Therefore, less bleeding is achieved especially in patients with anticoagulant therapy compared to B-TUVP as reported in our study. In a similar context, Chien-Hsu Che et al. concluded that diode laser prostatectomy can achieve excellent hemostasis, especially for those who were on anticoagulant therapy [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par33">Boeri et al. retrospectively analyzed 438 patients on anticoagulant or antiplatelet medications who underwent prostate enucleation using either holmium laser (HoLEP, n&#x02009;= 296, 67.6%) or bipolar transurethral (B-TUEP, n&#x02009;= 142, 32.4%) techniques. They found that patients with and without anticoagulant/antiplatelet (AC/AP) therapy exhibited comparable outcomes regarding operative time, hemoglobin drop, 2-month IPSS, and transfusion rates [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par34">In our study, patients managed by diode LVP showed shorter urinary irrigation time and early catheter removal compared to the B-TUVP group. Consequently, the diode LVP group showed early hospital discharge compared to the B-TUVP group.</p><p id="Par35">Within this framework, a randomized clinical trial was conducted on 115 patients (50 patients managed by diode laser vs 52 patients managed by TURP). It showed a significantly less postoperative catheterization time and shortened length of hospital stays [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par36">Sanjo et al. also showed comparable results between both groups (antithrombotic therapy vs. control group) in patients undergoing diode laser vaporization of prostate in terms of same median catheterization period (2 days) and the median hospital stay period (5 days) in both groups [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par37">Regarding functional outcomes in terms of postoperative Q-max, PVRU, and 6-month IPSS, we didn&#x02019;t report any significant differences between both groups.</p><p id="Par38">Multiple studies reported similar functional outcomes between TURP and diode laser [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par39">Our study's primary strength lies in its novelty as the first prospective randomized controlled trial directly comparing diode LVP and B-TUVP specifically in bleeding-prone BPH patients on antithrombotic medications, a critical and understudied population. The findings that demonstrating significantly less postoperative bleeding and faster early recovery with diode LVP offer valuable initial evidence for its potential advantages in this high-risk group. This prospective comparison provides a crucial foundation for future research aimed at optimizing surgical management in this challenging clinical context.</p><p id="Par40">Our study is not devoid of limitations. A modest sample size, lack of blinding or allocation concealment, the use of a per-protocol (PP) analysis as our primary approach, and shorter duration of follow-up are the major limitations of the study. Moreover, the lack of reporting preoperative coagulation profile was another shortcoming. Also, our study's findings are potentially limited by the absence of subgroup analysis for different anticoagulant and platelet inhibitor types, which could affect bleeding outcomes. Therefore, more randomized controlled trials with longer follow-up times and larger sample sizes are necessary.</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par41">Our study revealed that diode LVP of the prostate is a safer and less invasive treatment option for BPH compared to B-TUVP, reducing postoperative complications such as hemoglobin drop, hematuria, irrigation time, catheterization time, and hospital stay. However, both procedures show comparable functional outcomes and appear to be equally effective for IPSS, Q-Max, and PVRU in treating BPH. Briefly, the use of a high-powered diode laser (980 nm) can be considered a safe and practical alternative for B-TUVP in treating symptomatic BPH, especially in patients receiving anticoagulant/antiplatelet medications.</p></sec><sec id="Sec12" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="345_2025_5692_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 20 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>PH: protocol development, data analysis, manuscript writing, revision. S A. a: manuscript editing. MI: project development, manuscript editing. YM: project development, critical revision. MD: protocol development, data collection. MS: data analysis, manuscript editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par42">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Ethical approval and consent to participate</title><p id="Par43">All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by Faculty of medicine Ain Shames Institutional Review Board No. FWA 000017585.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par44">Not applicable.</p></notes><notes id="FPar4"><title>Informed consent</title><p id="Par45">Informed consent was obtained from all individual participants included in the study.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Gratzke</surname><given-names>C</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>Descazeaud</surname><given-names>A</given-names></name><name><surname>Drake</surname><given-names>MJ</given-names></name><name><surname>Madersbacher</surname><given-names>S</given-names></name><name><surname>Mamoulakis</surname><given-names>C</given-names></name><etal/></person-group><article-title>EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction</article-title><source>Eur Urol</source><year>2015</year><volume>67</volume><issue>6</issue><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.12.038</pub-id><pub-id pub-id-type="pmid">25613154</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67(6):1099&#x02013;1109<pub-id pub-id-type="pmid">25613154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Cornu</surname><given-names>J-N</given-names></name><name><surname>Ahyai</surname><given-names>S</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>de la Rosette</surname><given-names>J</given-names></name><name><surname>Gilling</surname><given-names>P</given-names></name><name><surname>Gratzke</surname><given-names>C</given-names></name><etal/></person-group><article-title>A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update</article-title><source>Eur Urol</source><year>2015</year><volume>67</volume><issue>6</issue><fpage>1066</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2014.06.017</pub-id><pub-id pub-id-type="pmid">24972732</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C et al (2015) A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 67(6):1066&#x02013;1096<pub-id pub-id-type="pmid">24972732</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Perri</surname><given-names>D</given-names></name><name><surname>Pacchetti</surname><given-names>A</given-names></name><name><surname>Morini</surname><given-names>E</given-names></name><name><surname>Besana</surname><given-names>U</given-names></name><name><surname>Saredi</surname><given-names>G</given-names></name><name><surname>Pastore</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Prognostic factors predicting bleeding after discharge requiring readmission after thulium laser enucleation of the prostate (ThuLEP)</article-title><source>Soc Int Urol J</source><year>2023</year><volume>4</volume><issue>5</issue><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.48083/LXOI8745</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Perri D, Pacchetti A, Morini E, Besana U, Saredi G, Pastore AL et al (2023) Prognostic factors predicting bleeding after discharge requiring readmission after thulium laser enucleation of the prostate (ThuLEP). Soc Int Urol J 4(5):385&#x02013;391</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahyai</surname><given-names>SA</given-names></name><name><surname>Gilling</surname><given-names>P</given-names></name><name><surname>Kaplan</surname><given-names>SA</given-names></name><name><surname>Kuntz</surname><given-names>RM</given-names></name><name><surname>Madersbacher</surname><given-names>S</given-names></name><name><surname>Montorsi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement</article-title><source>Eur Urol</source><year>2010</year><volume>58</volume><issue>3</issue><fpage>384</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2010.06.005</pub-id><pub-id pub-id-type="pmid">20825758</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F et al (2010) Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 58(3):384&#x02013;397<pub-id pub-id-type="pmid">20825758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Lusuardi</surname><given-names>L</given-names></name><name><surname>Myatt</surname><given-names>A</given-names></name><name><surname>Sieberer</surname><given-names>M</given-names></name><name><surname>Jeschke</surname><given-names>S</given-names></name><name><surname>Zimmermann</surname><given-names>R</given-names></name><name><surname>Janetschek</surname><given-names>G</given-names></name></person-group><article-title>Safety and efficacy of eraser laser enucleation of the prostate: preliminary report</article-title><source>J Urol</source><year>2011</year><volume>186</volume><issue>5</issue><fpage>1967</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2011.07.026</pub-id><pub-id pub-id-type="pmid">21944122</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lusuardi L, Myatt A, Sieberer M, Jeschke S, Zimmermann R, Janetschek G (2011) Safety and efficacy of eraser laser enucleation of the prostate: preliminary report. J Urol 186(5):1967&#x02013;1971<pub-id pub-id-type="pmid">21944122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuki</surname><given-names>H</given-names></name><name><surname>Kuwahara</surname><given-names>Y</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Shiroki</surname><given-names>R</given-names></name><etal/></person-group><article-title>Transurethral resection in saline vaporization: evaluation of clinical efficacy and prostate volume</article-title><source>Urology</source><year>2012</year><volume>79</volume><issue>3</issue><fpage>665</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2011.09.044</pub-id><pub-id pub-id-type="pmid">22130360</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Otsuki H, Kuwahara Y, Kosaka T, Tsukamoto T, Nakamura K, Shiroki R et al (2012) Transurethral resection in saline vaporization: evaluation of clinical efficacy and prostate volume. Urology 79(3):665&#x02013;669<pub-id pub-id-type="pmid">22130360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Mithani</surname><given-names>MH</given-names></name><name><surname>Khalid</surname><given-names>SE</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Sharif</surname><given-names>I</given-names></name><name><surname>Awan</surname><given-names>AS</given-names></name><name><surname>Mithani</surname><given-names>S</given-names></name><etal/></person-group><article-title>Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: a prospective study</article-title><source>Investig Clin Urol</source><year>2018</year><volume>59</volume><issue>6</issue><fpage>392</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.4111/icu.2018.59.6.392</pub-id><pub-id pub-id-type="pmid">30402572</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mithani MH, Khalid SE, Khan SA, Sharif I, Awan AS, Mithani S et al (2018) Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: a prospective study. Investig Clin Urol 59(6):392&#x02013;398<pub-id pub-id-type="pmid">30402572</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Reich</surname><given-names>O</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name><name><surname>Siebels</surname><given-names>M</given-names></name><name><surname>Hofstetter</surname><given-names>A</given-names></name><name><surname>Stief</surname><given-names>CG</given-names></name><name><surname>Sulser</surname><given-names>T</given-names></name></person-group><article-title>High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients</article-title><source>J Urol</source><year>2005</year><volume>173</volume><issue>1</issue><fpage>158</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1097/01.ju.0000146631.14200.d4</pub-id><pub-id pub-id-type="pmid">15592063</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T (2005) High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 173(1):158&#x02013;160<pub-id pub-id-type="pmid">15592063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Rieken</surname><given-names>M</given-names></name><name><surname>Bachmann</surname><given-names>A</given-names></name></person-group><article-title>Laser treatment of benign prostate enlargement&#x02014;which laser for which prostate?</article-title><source>Nat Rev Urol</source><year>2014</year><volume>11</volume><issue>3</issue><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2014.23</pub-id><pub-id pub-id-type="pmid">24595121</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Rieken M, Bachmann A (2014) Laser treatment of benign prostate enlargement&#x02014;which laser for which prostate? Nat Rev Urol 11(3):142&#x02013;152<pub-id pub-id-type="pmid">24595121</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt-Nordahl</surname><given-names>G</given-names></name><name><surname>Huckele</surname><given-names>S</given-names></name><name><surname>Honeck</surname><given-names>P</given-names></name><name><surname>Alken</surname><given-names>P</given-names></name><name><surname>Knoll</surname><given-names>T</given-names></name><name><surname>Michel</surname><given-names>MS</given-names></name><etal/></person-group><article-title>980-nm diode laser: a novel laser technology for vaporization of the prostate</article-title><source>Eur Urol</source><year>2007</year><volume>52</volume><issue>6</issue><fpage>1723</fpage><lpage>1728</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2007.06.029</pub-id><pub-id pub-id-type="pmid">17611013</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS et al (2007) 980-nm diode laser: a novel laser technology for vaporization of the prostate. Eur Urol 52(6):1723&#x02013;1728<pub-id pub-id-type="pmid">17611013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukazawa</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Takanashi</surname><given-names>M</given-names></name><name><surname>Shinoki</surname><given-names>R</given-names></name><name><surname>Tabei</surname><given-names>T</given-names></name><name><surname>Kawahara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Short-term efficacy and safety of second generation bipolar transurethral vaporization of the prostate (B-TUVP) for large benign prostate enlargement: results from a retrospective feasibility study</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><issue>12</issue><fpage>e0261586</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0261586</pub-id><pub-id pub-id-type="pmid">34914804</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Fukazawa T, Ito H, Takanashi M, Shinoki R, Tabei T, Kawahara T et al (2021) Short-term efficacy and safety of second generation bipolar transurethral vaporization of the prostate (B-TUVP) for large benign prostate enlargement: results from a retrospective feasibility study. PLoS ONE 16(12):e0261586<pub-id pub-id-type="pmid">34914804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Keeffe</surname><given-names>AG</given-names></name><name><surname>Ambler</surname><given-names>G</given-names></name><name><surname>Barber</surname><given-names>JA</given-names></name></person-group><article-title>Sample size calculations based on a difference in medians for positively skewed outcomes in health care studies</article-title><source>BMC Med Res Methodol</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s12874-017-0426-1</pub-id><pub-id pub-id-type="pmid">29197347</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">O&#x02019;Keeffe AG, Ambler G, Barber JA (2017) Sample size calculations based on a difference in medians for positively skewed outcomes in health care studies. BMC Med Res Methodol 17(1):157<pub-id pub-id-type="pmid">29197347</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>JVA</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Borofsky</surname><given-names>M</given-names></name><name><surname>Omar</surname><given-names>MI</given-names></name><name><surname>Escobar Liquitay</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis</article-title><source>Cochrane Database Syst Rev</source><year>2021</year><pub-id pub-id-type="doi">10.1002/14651858.CD013656.pub2</pub-id><pub-id pub-id-type="pmid">34850383</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Franco JVA, Jung JH, Imamura M, Borofsky M, Omar MI, Escobar Liquitay CM et al (2021) Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta-analysis. Cochrane Database Syst Rev. 10.1002/14651858.CD013656.pub2<pub-id pub-id-type="pmid">34850383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Taleb</surname><given-names>A</given-names></name><name><surname>El-Shaer</surname><given-names>W</given-names></name><name><surname>Kandeel</surname><given-names>W</given-names></name><name><surname>Gharib</surname><given-names>T</given-names></name><name><surname>Elshaer</surname><given-names>A</given-names></name></person-group><article-title>Bipolar plasmakinetic enucleoresection of the prostate: our experience with 245 patients for 3 years of follow-up</article-title><source>J Endourol</source><year>2017</year><volume>31</volume><issue>3</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1089/end.2016.0746</pub-id><pub-id pub-id-type="pmid">28073286</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Abou-Taleb A, El-Shaer W, Kandeel W, Gharib T, Elshaer A (2017) Bipolar plasmakinetic enucleoresection of the prostate: our experience with 245 patients for 3 years of follow-up. J Endourol 31(3):300&#x02013;306<pub-id pub-id-type="pmid">28073286</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Hong</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Bian</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name></person-group><article-title>A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up</article-title><source>Lasers Med Sci</source><year>2016</year><volume>31</volume><issue>4</issue><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1007/s10103-016-1883-1</pub-id><pub-id pub-id-type="pmid">26822403</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Wu G, Hong Z, Li C, Bian C, Huang S, Wu D (2016) A comparative study of diode laser and plasmakinetic in transurethral enucleation of the prostate for treating large volume benign prostatic hyperplasia: a randomized clinical trial with 12-month follow-up. Lasers Med Sci 31(4):599&#x02013;604<pub-id pub-id-type="pmid">26822403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Tzou</surname><given-names>K-Y</given-names></name><name><surname>Kao</surname><given-names>W-T</given-names></name><name><surname>Lan</surname><given-names>C-Y</given-names></name><name><surname>Ho</surname><given-names>C-H</given-names></name><name><surname>Chiang</surname><given-names>Y-T</given-names></name><name><surname>Chen</surname><given-names>K-C</given-names></name></person-group><article-title>Management of prostate enlargement with acute urinary retention: diode laser vaporization in combination with bipolar transurethral resection of the prostate</article-title><source>Urol Sci</source><year>2016</year><volume>27</volume><issue>1</issue><fpage>31</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.urols.2015.12.002</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Tzou K-Y, Kao W-T, Lan C-Y, Ho C-H, Chiang Y-T, Chen K-C (2016) Management of prostate enlargement with acute urinary retention: diode laser vaporization in combination with bipolar transurethral resection of the prostate. Urol Sci 27(1):31&#x02013;34</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaghi</surname><given-names>MR</given-names></name><name><surname>Mazloomfard</surname><given-names>MM</given-names></name><name><surname>Mokhtarpour</surname><given-names>H</given-names></name><name><surname>Moeini</surname><given-names>A</given-names></name></person-group><article-title>Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: randomized clinical trial with 2-year follow-up</article-title><source>Urology</source><year>2014</year><volume>84</volume><issue>3</issue><fpage>526</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2014.05.027</pub-id><pub-id pub-id-type="pmid">25168526</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Razzaghi MR, Mazloomfard MM, Mokhtarpour H, Moeini A (2014) Diode laser (980 nm) vaporization in comparison with transurethral resection of the prostate for benign prostatic hyperplasia: randomized clinical trial with 2-year follow-up. Urology 84(3):526&#x02013;532<pub-id pub-id-type="pmid">25168526</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C-H</given-names></name><name><surname>Chiang</surname><given-names>P-H</given-names></name><name><surname>Chuang</surname><given-names>Y-C</given-names></name><name><surname>Lee</surname><given-names>W-C</given-names></name><name><surname>Chen</surname><given-names>Y-T</given-names></name><name><surname>Lee</surname><given-names>W-C</given-names></name></person-group><article-title>Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser</article-title><source>Urology</source><year>2010</year><volume>75</volume><issue>3</issue><fpage>658</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.urology.2009.09.033</pub-id><pub-id pub-id-type="pmid">20035978</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Chen C-H, Chiang P-H, Chuang Y-C, Lee W-C, Chen Y-T, Lee W-C (2010) Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. Urology 75(3):658&#x02013;663<pub-id pub-id-type="pmid">20035978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Boeri</surname><given-names>L</given-names></name><name><surname>Capogrosso</surname><given-names>P</given-names></name><name><surname>Ventimiglia</surname><given-names>E</given-names></name><name><surname>Fontana</surname><given-names>M</given-names></name><name><surname>Sampogna</surname><given-names>G</given-names></name><name><surname>Zanetti</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Clinical comparison of holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate in patients under either anticoagulation or antiplatelet therapy</article-title><source>Eur Urol Focus</source><year>2020</year><volume>6</volume><issue>4</issue><fpage>720</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.euf.2019.03.002</pub-id><pub-id pub-id-type="pmid">30872124</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Boeri L, Capogrosso P, Ventimiglia E, Fontana M, Sampogna G, Zanetti SP et al (2020) Clinical comparison of holmium laser enucleation of the prostate and bipolar transurethral enucleation of the prostate in patients under either anticoagulation or antiplatelet therapy. Eur Urol Focus 6(4):720&#x02013;728<pub-id pub-id-type="pmid">30872124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjo</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>Shinojima</surname><given-names>T</given-names></name><name><surname>Yasumizu</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: a prospective survey</article-title><source>Asian J Endosc Surg</source><year>2022</year><volume>15</volume><issue>3</issue><fpage>585</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1111/ases.13057</pub-id><pub-id pub-id-type="pmid">35307968</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Sanjo T, Tanaka N, Shinojima T, Yasumizu Y, Takeda T, Matsumoto K et al (2022) Endoscopic vaporization of benign prostatic hyperplasia using a contact 980 nm diode laser under antithrombotic therapy: a prospective survey. Asian J Endosc Surg 15(3):585&#x02013;590<pub-id pub-id-type="pmid">35307968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Cetinkaya</surname><given-names>M</given-names></name><name><surname>Onem</surname><given-names>K</given-names></name><name><surname>Rifaioglu</surname><given-names>MM</given-names></name><name><surname>Yalcin</surname><given-names>V</given-names></name></person-group><article-title>980-Nm diode laser vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: randomized controlled study</article-title><source>Urol J</source><year>2015</year><volume>12</volume><issue>5</issue><fpage>2355</fpage><lpage>2361</lpage><pub-id pub-id-type="pmid">26571321</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cetinkaya M, Onem K, Rifaioglu MM, Yalcin V (2015) 980-Nm diode laser vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia: randomized controlled study. Urol J 12(5):2355&#x02013;2361<pub-id pub-id-type="pmid">26571321</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>